Introduction to Refractory Ulcerative

What is/are Refractory Ulcerative?

Refractory Ulcerative - We have written on the off-label use of subcutaneous golimumab, which helped to induce and maintain remission on a low-weight biologically experienced child with steroid-refractory ulcerative colitis flare. ^[1] BACKGROUND We evaluated whether integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission rate in refractory ulcerative colitis (UC). ^[2] We report a 60-year-old male who was transferred to our hospital for the operation because of refractory ulcerative colitis (UC). ^[3] Medical rescue therapy for patients with severe steroid-refractory ulcerative colitis (UC) consists of intravenous (IV) cyclosporine or infliximab and remains limited. ^[4] A multicenter clinical trial is currently underway in Japan for patients with refractory ulcerative colitis and Crohn’s disease. ^[5] In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks. ^[6] However, the treatment of patients with severe steroid-refractory ulcerative colitis remains a serious challenge to clinicians. ^[7] We evaluated if integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission in refractory ulcerative colitis (UC) or have an independent effect on remission. ^[8] Tacrolimus (Tac) is an effective remission inducer of refractory ulcerative colitis (UC). ^[9] Background: Infliximab (IFX) and calcineurin inhibitors (cyclosporine [CYS] and tacrolimus [TAC]) were considered as rescue therapy in steroid-refractory ulcerative colitis (UC). ^[10] Thirteen therapy-refractory ulcerative proctitis patients were endoscopically injected bone marrow-derived allogeneic MSCs from healthy donors. ^[11] Background The immunomodulatory and antiangiogenic effects of thalidomide have been demonstrated in a number of refractory ulcerative oromucosal conditions, including recurrent aphthous stomatitis (RAS), Behcet disease, erythema multiforme (EM), erosive lichen planus, and orofacial granulomatosis (OFG). ^[12] Background/Aims Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). ^[13] BACKGROUND Anti-tumour necrosis factor (TNF) agents are the mainstay of long-term treatment for refractory ulcerative colitis. ^[14] Lack of efficacy, infusion reaction and drug eruption: 21 case reports In a retrospective study involving 123 patients with refractory ulcerative colitis (UC) treated between July 2010 and August 2018 across various hospitals in Japan, 21 patients [ages and sexes not stated] were described who exhibited lack of efficacy (18 patients), developed infusion reactions (2 patients) or developed eruption (1 patient) during treatment with adalimumab, golimumab or infliximab [durations of treatments to reactions onsets and outcomes not stated]. ^[15] BACKGROUND It is a crucial issue for patients with refractory ulcerative colitis (UC), including steroid-dependent and steroid-refractory patients, to achieve and maintain steroid-free remission. ^[16] Background and Aims The objective of this study was to examine the modulating effect of an appendectomy on the disease course of therapy-refractory ulcerative colitis [UC] patients, and to analyse appendiceal pathological characteristics predictive of pathological response. ^[17] To assess the effectiveness and safety of combining granulocyte‐monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). ^[18] Between February 2017 and June 2018 eight patients with steroid-refractory ulcerative colitis given ciclosporin and infliximab therapy in succession were identified. ^[19] Editor We thank Herfarth and Barnes for their valuable comment and justified questions regarding our paper analysing the effect of appendicectomy in patients with refractory ulcerative colitis (UC)1. ^[20] Editor We thank Dai and Jiang for their interesting comment regarding our paper analysing the effect of appendicectomy in patients with refractory ulcerative colitis (UC)1. ^[21] This study aimed to analyse the effect of appendicectomy in patients with refractory ulcerative colitis. ^[22] Fifty patients with refractory ulcerative colitis were randomly distributed to either group I (n = 25): on adalimumab injection (160/80 mg) or group II (n = 25): on infliximab injection (5 mg/kg) along the term of induction. ^[23] Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. ^[24] We describe a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis consistent with a diagnosis of vanishing bile duct syndrome. ^[25] Case presentationWe present the case of a 14-year-old Caucasian boy with refractory ulcerative colitis, admitted to the Child Neuropsychiatry Unit of the Polyclinic Hospital of Bari in the course of his first-episode psychosis. ^[26] Background Infliximab pharmacokinetics in steroid-refractory ulcerative colitis (UC) suggest a need for higher dosing, but data concerning efficacy of intensification in this setting are lacking in children and inconsistent overall. ^[27] Background and ObjectivesTacrolimus is very effective at inducing remission in patients with refractory ulcerative colitis. ^[28] Background Mesalazine-refractory ulcerative proctitis is common, with a significant proportion of the patients requiring escalation to immunomodulators or biological therapy. ^[29] ’s study on appendicectomy for the treatment of therapy-refractory ulcerative colitis,1 which received over 10 000 impressions. ^[30] Background Although methotrexate (MTX) is used for refractory ulcerative colitis (UC) in clinical practice, there is still controversy about whether MTX is as effective in UC as that in Crohn’s disease (CD). ^[31] Background/Aims Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. ^[32] We herein report a case in which PAH developed in a patient with refractory ulcerative colitis during treatment with “Qing-Dai,” a Chinese herbal medicine. ^[33] A 40-year-old man with refractory ulcerative colitis (UC) was treated with tumor necrosis factor α inhibitor (anti-TNFα), infliximab. ^[34] Tacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). ^[35] Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. ^[36]

ileal pouch anal

A 30-year-old man with a history of medically refractory ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) for which he underwent three-stage total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) was evaluated for complaints of frequency, urgency of bowel movements, abdominal pain, and joint pain. ^[1] Pouchitis is the most common long-term complication in patients requiring colectomy ileal pouch-anal anastomosis with medically refractory ulcerative colitis or colitis-associated neoplasia. ^[2] BACKGROUND & AIMS Patients with primary sclerosing cholangitis (PSC) commonly undergo ileal pouch-anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC) or colorectal dysplasia. ^[3] CONCLUSION Technical failure of ileal pouch-anal anastomosis is elevated in patients with higher body mass index, with refractory ulcerative colitis, and/or extended immunosuppressive medication. ^[4] Crohn’s disease (CD) of the pouch and chronic pouchitis represent the most common long-term complications of total proctocolectomy and ileal pouch anal anastomosis (IPAA) for refractory ulcerative colitis (UC). ^[5] Surgical management for refractory ulcerative colitis (UC) has been restorative proctocolectomy (RP) with ileal-pouch-anal-anastomosis (IPAA) done as one to three stages, with safety and effectiveness of a single-stage operation unclear. ^[6] BACKGROUND Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. ^[7] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[8] Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice for patients with refractory ulcerative colitis, familial adenomatous polyposis, indeterminate colitis, and highly selected cases with Crohn’s colitis. ^[9] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the surgical treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[10] Ileal pouch-anal anastomosis (IPAA) followed by total proctocolectomy is routinely performed to patients with medically refractory ulcerative colitis or colitis-associated neoplasia with a goal of improved health and quality of life. ^[11] BACKGROUND/PURPOSE Colectomy with ileal pouch-anal anastomosis (IPAA) is the standard of care for patients with familial adenomatous polyposis (FAP) and refractory ulcerative colitis (UC). ^[12] Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the surgical treatment of choice for patients with medically refractory ulcerative colitis or with familial adenomatous polyposis (FAP). ^[13] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the gold standard surgical procedure for familial adenomatous polyposis, refractory ulcerative colitis or colitis-associated dysplasia. ^[14] Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the mainstay of surgical management for medically refractory ulcerative colitis as well as familial adenomatous polyposis. ^[15] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the surgical procedure of choice for patients with medically refractory ulcerative colitis (UC) or indeterminate colitis, UC with colonic dysplasia or neoplasia, and familial adenomatous polyposis. ^[16] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is widely accepted as the operation of choice for refractory ulcerative colitis (UC), UC with dysplasia or cancer, or familial adenomatous polyposis. ^[17]

year old female

In this video vignette, we present the case of a 21-year old female with medically refractory ulcerative colitis who previously underwent subtotal colectomy with an end ileostomy. ^[1] This is a clinical case report of a 52-year-old female patient with 30 years history of left-sided chronic ulcerative colitis controlled with standard of care (mesalamine and azathioprine) which subsequently relapsed and developed into active refractory ulcerative colitis. ^[2] Presentation of Case An 83-year-old female with refractory ulcerative colitis underwent a total proctocolectomy and end ileostomy. ^[3] Methods: An 83-year-old female underwent an elective total proctocolectomy and end ileostomy for refractory ulcerative colitis. ^[4]

Medically Refractory Ulcerative

A 30-year-old man with a history of medically refractory ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) for which he underwent three-stage total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) was evaluated for complaints of frequency, urgency of bowel movements, abdominal pain, and joint pain. ^[1] Pouchitis is the most common long-term complication in patients requiring colectomy ileal pouch-anal anastomosis with medically refractory ulcerative colitis or colitis-associated neoplasia. ^[2] BACKGROUND Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. ^[3] BackgroundPediatric patients with medically refractory ulcerative colitis (UC) often undergo an initial subtotal colectomy end ileostomy (STC-I). ^[4] Although restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) is an important surgical treatment for medically refractory ulcerative colitis, it is frequently complicated by pouchitis, a condition responsible for up to 8. ^[5] In this video vignette, we present the case of a 21-year old female with medically refractory ulcerative colitis who previously underwent subtotal colectomy with an end ileostomy. ^[6] Background Proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical procedure of choice for medically refractory ulcerative colitis and familial adenomatous polyposis. ^[7] Restorative proctocolectomy with ileal “J,” “W,” or “S” pouch-anal anastomosis (IPAA) is the treatment of choice in the majority of patients who require colectomy for medically refractory ulcerative colitis (UC), colitis-associated dysplasia and/or cancer, as well as familial adenomatous polyposis (FAP). ^[8] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[9] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the surgical treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[10] Ileal pouch-anal anastomosis (IPAA) followed by total proctocolectomy is routinely performed to patients with medically refractory ulcerative colitis or colitis-associated neoplasia with a goal of improved health and quality of life. ^[11] Many surgeons consider total proctectomy with ileal pouch–anal anastomosis as the treatment of choice for patients with medically refractory ulcerative colitis or ulcerative colitis with dysplasia. ^[12] She had previously undergone a subtotal colectomy with an end ileostomy for medically refractory ulcerative colitis in 2008. ^[13] BACKGROUND A restorative proctocolectomy with an IPAA is the surgical treatment of choice for medically refractory ulcerative colitis. ^[14] Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the surgical treatment of choice for patients with medically refractory ulcerative colitis or with familial adenomatous polyposis (FAP). ^[15] Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the mainstay of surgical management for medically refractory ulcerative colitis as well as familial adenomatous polyposis. ^[16] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the surgical procedure of choice for patients with medically refractory ulcerative colitis (UC) or indeterminate colitis, UC with colonic dysplasia or neoplasia, and familial adenomatous polyposis. ^[17] INTRODUCTION Restorative proctocolectomy is a surgical treatment for patients with medically refractory ulcerative colitis and some cases of familial adenomatous polyposis. ^[18] The aim of this study was to describe the rate and risk factors for PMVT in patients undergoing surgery for medically refractory ulcerative colitis (UC). ^[19]

Treatment Refractory Ulcerative

Introduction Tofacitinib is an oral, small molecule Janus kinase inhibitor, which recently received NICE approval for the treatment of moderate to severe treatment refractory ulcerative colitis. ^[1] Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. ^[2]

Chronic Refractory Ulcerative

Total colectomy (TC) is often considered a curative procedure for patients with chronic refractory ulcerative colitis (UC) or acute severe colitis. ^[1] BACKGROUND In patients with chronic refractory ulcerative colitis (UC) the precise timing for indication to colectomy is unclear. ^[2]

refractory ulcerative colitis

We have written on the off-label use of subcutaneous golimumab, which helped to induce and maintain remission on a low-weight biologically experienced child with steroid-refractory ulcerative colitis flare. ^[1] A 30-year-old man with a history of medically refractory ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) for which he underwent three-stage total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) was evaluated for complaints of frequency, urgency of bowel movements, abdominal pain, and joint pain. ^[2] BACKGROUND We evaluated whether integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission rate in refractory ulcerative colitis (UC). ^[3] We report a 60-year-old male who was transferred to our hospital for the operation because of refractory ulcerative colitis (UC). ^[4] Pouchitis is the most common long-term complication in patients requiring colectomy ileal pouch-anal anastomosis with medically refractory ulcerative colitis or colitis-associated neoplasia. ^[5] Medical rescue therapy for patients with severe steroid-refractory ulcerative colitis (UC) consists of intravenous (IV) cyclosporine or infliximab and remains limited. ^[6] Indigo Naturalis, also known as Qing Dai (QD) is a compound obtained from Indigofera tinctoria, Isatis tinctoria, and Polygonum tinctoria and is known to ameliorate refractory ulcerative colitis (UC) by an unknown mechanism. ^[7] A multicenter clinical trial is currently underway in Japan for patients with refractory ulcerative colitis and Crohn’s disease. ^[8] In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks. ^[9] However, the treatment of patients with severe steroid-refractory ulcerative colitis remains a serious challenge to clinicians. ^[10] BACKGROUND & AIMS Patients with primary sclerosing cholangitis (PSC) commonly undergo ileal pouch-anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC) or colorectal dysplasia. ^[11] CONCLUSION Technical failure of ileal pouch-anal anastomosis is elevated in patients with higher body mass index, with refractory ulcerative colitis, and/or extended immunosuppressive medication. ^[12] We evaluated if integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission in refractory ulcerative colitis (UC) or have an independent effect on remission. ^[13] Crohn’s disease (CD) of the pouch and chronic pouchitis represent the most common long-term complications of total proctocolectomy and ileal pouch anal anastomosis (IPAA) for refractory ulcerative colitis (UC). ^[14] Tacrolimus (Tac) is an effective remission inducer of refractory ulcerative colitis (UC). ^[15] Background: Infliximab (IFX) and calcineurin inhibitors (cyclosporine [CYS] and tacrolimus [TAC]) were considered as rescue therapy in steroid-refractory ulcerative colitis (UC). ^[16] Total colectomy (TC) is often considered a curative procedure for patients with chronic refractory ulcerative colitis (UC) or acute severe colitis. ^[17] Subtotal colectomy was performed for steroid refractory ulcerative colitis. ^[18] Surgical management for refractory ulcerative colitis (UC) has been restorative proctocolectomy (RP) with ileal-pouch-anal-anastomosis (IPAA) done as one to three stages, with safety and effectiveness of a single-stage operation unclear. ^[19] Background/Aims Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). ^[20] BACKGROUND Anti-tumour necrosis factor (TNF) agents are the mainstay of long-term treatment for refractory ulcerative colitis. ^[21] Lack of efficacy, infusion reaction and drug eruption: 21 case reports In a retrospective study involving 123 patients with refractory ulcerative colitis (UC) treated between July 2010 and August 2018 across various hospitals in Japan, 21 patients [ages and sexes not stated] were described who exhibited lack of efficacy (18 patients), developed infusion reactions (2 patients) or developed eruption (1 patient) during treatment with adalimumab, golimumab or infliximab [durations of treatments to reactions onsets and outcomes not stated]. ^[22] BACKGROUND Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. ^[23] BACKGROUND It is a crucial issue for patients with refractory ulcerative colitis (UC), including steroid-dependent and steroid-refractory patients, to achieve and maintain steroid-free remission. ^[24] BackgroundPediatric patients with medically refractory ulcerative colitis (UC) often undergo an initial subtotal colectomy end ileostomy (STC-I). ^[25] Although restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) is an important surgical treatment for medically refractory ulcerative colitis, it is frequently complicated by pouchitis, a condition responsible for up to 8. ^[26] Background and Aims The objective of this study was to examine the modulating effect of an appendectomy on the disease course of therapy-refractory ulcerative colitis [UC] patients, and to analyse appendiceal pathological characteristics predictive of pathological response. ^[27] In this video vignette, we present the case of a 21-year old female with medically refractory ulcerative colitis who previously underwent subtotal colectomy with an end ileostomy. ^[28] This is a clinical case report of a 52-year-old female patient with 30 years history of left-sided chronic ulcerative colitis controlled with standard of care (mesalamine and azathioprine) which subsequently relapsed and developed into active refractory ulcerative colitis. ^[29] To assess the effectiveness and safety of combining granulocyte‐monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). ^[30] Presentation of Case An 83-year-old female with refractory ulcerative colitis underwent a total proctocolectomy and end ileostomy. ^[31] Background Proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical procedure of choice for medically refractory ulcerative colitis and familial adenomatous polyposis. ^[32] Methods: An 83-year-old female underwent an elective total proctocolectomy and end ileostomy for refractory ulcerative colitis. ^[33] Stellingwerf (Amsterdam, The Netherlands) presented “Therapy refractory ulcerative colitis patients may benefit from appendectomy; Long-term clinical results from a multicenter prospective cohort series”. ^[34] Between February 2017 and June 2018 eight patients with steroid-refractory ulcerative colitis given ciclosporin and infliximab therapy in succession were identified. ^[35] Restorative proctocolectomy with ileal “J,” “W,” or “S” pouch-anal anastomosis (IPAA) is the treatment of choice in the majority of patients who require colectomy for medically refractory ulcerative colitis (UC), colitis-associated dysplasia and/or cancer, as well as familial adenomatous polyposis (FAP). ^[36] Editor We thank Herfarth and Barnes for their valuable comment and justified questions regarding our paper analysing the effect of appendicectomy in patients with refractory ulcerative colitis (UC)1. ^[37] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[38] Editor We thank Dai and Jiang for their interesting comment regarding our paper analysing the effect of appendicectomy in patients with refractory ulcerative colitis (UC)1. ^[39] Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice for patients with refractory ulcerative colitis, familial adenomatous polyposis, indeterminate colitis, and highly selected cases with Crohn’s colitis. ^[40] This study aimed to analyse the effect of appendicectomy in patients with refractory ulcerative colitis. ^[41] Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the surgical treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia. ^[42] Ileal pouch-anal anastomosis (IPAA) followed by total proctocolectomy is routinely performed to patients with medically refractory ulcerative colitis or colitis-associated neoplasia with a goal of improved health and quality of life. ^[43] Many surgeons consider total proctectomy with ileal pouch–anal anastomosis as the treatment of choice for patients with medically refractory ulcerative colitis or ulcerative colitis with dysplasia. ^[44] BACKGROUND/PURPOSE Colectomy with ileal pouch-anal anastomosis (IPAA) is the standard of care for patients with familial adenomatous polyposis (FAP) and refractory ulcerative colitis (UC). ^[45] Fifty patients with refractory ulcerative colitis were randomly distributed to either group I (n = 25): on adalimumab injection (160/80 mg) or group II (n = 25): on infliximab injection (5 mg/kg) along the term of induction. ^[46] Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. ^[47] She had previously undergone a subtotal colectomy with an end ileostomy for medically refractory ulcerative colitis in 2008. ^[48] We describe a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis consistent with a diagnosis of vanishing bile duct syndrome. ^[49] Case presentationWe present the case of a 14-year-old Caucasian boy with refractory ulcerative colitis, admitted to the Child Neuropsychiatry Unit of the Polyclinic Hospital of Bari in the course of his first-episode psychosis. ^[50]

refractory ulcerative proctitis

Thirteen therapy-refractory ulcerative proctitis patients were endoscopically injected bone marrow-derived allogeneic MSCs from healthy donors. ^[1] Background Mesalazine-refractory ulcerative proctitis is common, with a significant proportion of the patients requiring escalation to immunomodulators or biological therapy. ^[2]